Collegium Pharmaceutical reported GAAP profitability with $0.5 million in net income and non-GAAP net income of $31.2 million in Q1 2020. Xtampza ER prescriptions grew 30% year-over-year. The company updated its 2020 guidance to reflect COVID-19 impact.
Xtampza ER total prescriptions grew 30% year-over-year, reaching 136,736.
Xtampza ER market share of the oxycodone extended-release market increased to 21.8%.
The number of unique prescribers grew to 14,600.
The company closed the acquisition of the U.S. rights to the Nucynta Franchise from Assertio Therapeutics, Inc.
Collegium updated its full-year 2020 financial guidance.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance